The nation of Zimbabwe has declined a substantial American healthcare agreement valued at $367m (272 million pounds) spanning five years due to Washington's request for sensitive biological samples.
The decision became public following a official document dated December was disclosed, indicating that Head of State Emmerson Mnangagwa deemed the agreement was "lopsided".
A government representative later explained that the US was demanding access to biological samples for research and commercial purposes while was unwilling to guarantee the benefits from future vaccines.
"We will now turn to the challenging and unfortunate task of ending our support in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy said the US had provided over $1.9bn for health programmes to Zimbabwe over the last twenty years.
A doctors' association in Zimbabwe has appealed for more dialogue to find a deal suitable to both sides so the country's critical HIV treatment initiative can proceed.
Broader Context
This rejection follows a similar case in neighbouring Kenya, where a court suspended a related deal with the US after concerns were raised about the security of citizens' medical information.
Since resuming office recently, US President Donald Trump has reduced foreign aid and closed the US Agency for International Development (USAID).
USAID had administered assistance for the American government, but Trump argued its expenditure was "inefficient" and his government was seeking government-to-government deals to boost openness and responsibility.
Based on statements, 16 African countries have so far signed these new agreements, constituting over $18.3bn in committed funds.
Specifics of the Rejected Agreement
The funds for Zimbabwe would have gone towards "tackling HIV/Aids, tuberculosis, malaria, maternal and child health, and preparing for epidemics".
"We are confident this cooperation would have delivered extraordinary advantages for Zimbabwean communities, particularly the 1.2 million presently on HIV treatment through US-supported initiatives," Tremont added.
However, official spokesman Nick Mangwana said the proposed deal was "unequal".
"Zimbabwe was being asked to share its genetic material and health information over an extended period, with no equivalent assurance of benefiting from any medical innovations – such as new medicines or tests – that could be developed from that provided information," he stated.
"In essence, our nation would provide the raw materials for scientific discovery with no assurance that the final treatments would be available to our population if a future health crisis emerge."
National Interest and International Frameworks
Mangwana further pointed out that the US's withdrawal from the World Health Organization (WHO) and its push of one-on-one health agreements were disrupting frameworks previously set up via the international health agency.
Mangwana cited its Pandemic Benefit-Sharing scheme created to manage future pandemics.
"This system is intended to ensure that when a country contributes its samples, the resulting advantages – such as medicines and cures – are distributed fairly, not commercialised exclusively by those with the capability to create them."
These objections regarding the US deal "must not be interpreted as opposition to America," he added.
"We encourage continued discussions with our US partners on how future collaboration might be arranged in a way that honours the independence and dignity of both nations."
Health Experts Reaction
Medical experts stated it understood the official position, but suggested that negotiations must proceed since much of the country's Aids initiatives were funded by international support.
"If specific concerns exist, such as those relating to information security or implementation frameworks, these can frequently be resolved through technical clarification and mutually agreed protections," the group said.
The situation highlights the continuing debate between receiving crucial foreign assistance and protecting national sovereignty in an ever more data-driven world.